HIGHLIGHTS
- who: W. A. Bashari from the of Metabolic Science, University of Cambridge and National Biomedical Campus, Cambridge, UK have published the paper: 11C-methionine PET aids localization of microprolactinomas in patients with intolerance or resistance to dopamine agonist therapy, in the Journal: (JOURNAL)
- what: The authors show that functional imaging can confirm or refute the suspected site of a microprolactinoma queried on clinical MRI and reveal the location of an adenoma when MRI is negative. The authors report the initial experience with Met-PET/MRCR in 13 patients with microprolactinomas and dopamine agonist intolerance or . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.